Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2017

Mar 4, 2017

32134_dirs_2017-03-03_b72cbb56-5707-43dd-92ac-ccbf559e373e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-03-02

Reporting Person: Labrucherie Gil M (SVP & Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-02 Common Stock M 167506 $6.34 Acquired 236776 Direct
2017-03-02 Common Stock S 167506 $15.15 Disposed 69270 Direct
2017-03-03 Common Stock M 7494 $6.34 Acquired 76764 Direct
2017-03-03 Common Stock S 7494 $15.21 Disposed 69270 Direct
2017-03-03 Common Stock M 25000 $9.24 Acquired 94270 Direct
2017-03-03 Common Stock S 25000 $15.21 Disposed 69270 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-02 Stock Option $6.34 M 167506 Disposed 2017-06-09 Common Stock (167506) Direct
2017-03-03 Stock Option $6.34 M 7494 Disposed 2017-06-09 Common Stock (7494) Direct
2017-03-03 Stock Option $9.24 M 25000 Disposed 2017-11-17 Common Stock (25000) Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 175,000 stock options scheduled to expire on June 9, 2017.

F2: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 2,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).

F3: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F4: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie on March 14, 2016 related to 25,000 stock options scheduled to expire on November 17, 2017.